Assertion: warfarin | /r/HasProperty | hazard ratio
Facets:
Source sentences:
text: Nevertheless, the validity of the data from the ROCKET-AF trial has recently been questioned owing to use of an inaccurate point-of-care device (Hemosense INratio; HemoSense, San Jose, CA).28 A US Food and Drug Administration mandated post hoc analysis of the trial data examined bleeding outcomes in patients with chronic inflammation, acute inflammation, or hematocrit levels out of range.29 Specifically for the outcome of major bleeding, treatment with rivaroxaban was favoured compared with warfarin (hazard ratio 0.87, 95% confidence interval 0.70 to 1.08) in the subgroup of patients with none of the conditions; whereas the hazard ratio in patients with any of the conditions was 1.18 (0.98 to 1.42).